These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 24809328)

  • 1. Understanding the molecular dynamics of type-2 diabetes drug target DPP-4 and its interaction with Sitagliptin and inhibitor Diprotin-A.
    Chakraborty C; Hsu MJ; Agoramoorthy G
    Cell Biochem Biophys; 2014 Nov; 70(2):907-22. PubMed ID: 24809328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Martins MCMR; Pantaleao SQ; de Oliveira Almeida M; Weber KC; Honorio KM
    Med Chem; 2021; 17(3):247-263. PubMed ID: 31995015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilisation of the isobole methodology to study dietary peptide-drug and peptide-peptide interactive effects on dipeptidyl peptidase IV (DPP-IV) inhibition.
    Nongonierma AB; FitzGerald RJ
    Food Funct; 2015 Jan; 6(1):313-20. PubMed ID: 25477187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).
    Gallwitz B
    Drugs Today (Barc); 2007 Nov; 43(11):801-14. PubMed ID: 18174966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation.
    Meduru H; Wang YT; Tsai JJ; Chen YC
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Zerilli T; Pyon EY
    Clin Ther; 2007 Dec; 29(12):2614-34. PubMed ID: 18201579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
    Abel T; Fehér J
    Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical review of sitagliptin: a DPP-4 inhibitor.
    Garg K; Tripathi CD; Kumar S
    J Assoc Physicians India; 2013 Sep; 61(9):645-9. PubMed ID: 24772702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sitagliptin: a review.
    Subbarayan S; Kipnes M
    Expert Opin Pharmacother; 2011 Jul; 12(10):1613-22. PubMed ID: 21651449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
    Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors.
    Liu Y; Si M; Tang L; Shangguan S; Wu H; Li J; Wu P; Ma X; Liu T; Hu Y
    Bioorg Med Chem; 2013 Sep; 21(18):5679-87. PubMed ID: 23938053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
    Mu J; Petrov A; Eiermann GJ; Woods J; Zhou YP; Li Z; Zycband E; Feng Y; Zhu L; Roy RS; Howard AD; Li C; Thornberry NA; Zhang BB
    Eur J Pharmacol; 2009 Nov; 623(1-3):148-54. PubMed ID: 19765579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
    Takai S; Sakonjo H; Jin D
    J Pharmacol Sci; 2014; 125(4):386-93. PubMed ID: 25030743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
    Pei Z
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ
    Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.